UBS Group
LXEO icon

UBS Group’s Lexeo Therapeutics LXEO Stock Holding History

UBS Group’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.85M Buy
321,737
+40,654
+14% +$288K ﹤0.01% 5048
2025
Q4 		$2.79M Buy
281,083
+31,174
+12% +$284K ﹤0.01% 4644
2025
Q3 		$1.66M Sell
249,909
-21,995
-8% -$106K ﹤0.01% 5139
2025
Q2 		$1.09M Buy
271,904
+239,822
+748% +$789K ﹤0.01% 5381
2025
Q1 		$111K Sell
32,082
-18,972
-37% -$84K ﹤0.01% 6971
2024
Q4 		$336K Buy
51,054
+39,942
+359% +$315K ﹤0.01% 6118
2024
Q3 		$100K Buy
11,112
+7,983
+255% +$95.2K ﹤0.01% 6369
2024
Q2 		$50.2K Sell
3,129
-7,238
-70% -$105K ﹤0.01% 6687
2024
Q1 		$163K Buy
+10,367
New +$162K ﹤0.01% 5985

Other funds holding LXEO

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group's LXEO Position: Q1 2026 in Review

UBS Group increased its Lexeo Therapeutics (LXEO) stake by 14% in Q1 2026, buying an estimated $288K and bringing the position to 321,737 shares worth $1.85M. The position accounts for ﹤0.01% of the portfolio, ranked #5048.

UBS Group first reported a position in LXEO in Q1 2024 and has held it in 9 quarters since. The position peaked at $2.79M in Q4 2025. 139 funds tracked by Wall St. Rank hold LXEO as of Q1 2026.

  • UBS Group held 321,737 shares of Lexeo Therapeutics worth $1.85M as of Q1 2026.
  • UBS Group bought 40,654 Lexeo Therapeutics shares in Q1 2026, an estimated $288K.
  • Lexeo Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #5048 holding.
  • UBS Group first reported a position in Lexeo Therapeutics in Q1 2024 and has held it in 9 quarters since.
  • UBS Group's Lexeo Therapeutics position peaked at $2.79M in Q4 2025.
  • 139 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.